To analyze the effectiveness and safety of zoledronic acid combined with chemotherapy for lung cancer spinal metastases, 96 patients with lung cancer spinal metastases were averagely classified into the experimental group (gemcitabine, cisplatin, and zoledronic acid) and the control group (gemcitabine and cisplatin). An optimized noise variance estimation algorithm (OMAPB) was proposed based on the maximum a posteriori Bayesian method (MAPB), and the algorithm was applied to the patient’s computed tomography (CT) scan. The results indicated that in terms of curative effect, the number of complete remission (CR), partial remission (PR) cases, effective rate, and clinical benefit rate of the test group was significantly higher than those of the control group. The number of progress disease (PD) cases was significantly lower than that of the control group ( P < 0.05 ). The disease progression time of the test group patients was 6.2 months, and the disease progression time of the control group patients was 3.7 months ( P < 0.05 ). The test group patients had 8 cases of bone marrow suppression and gastrointestinal reactions after treatment. In the test group, there were 8 cases of bone marrow suppression, 9 cases of gastrointestinal reaction, 3 cases of fever, 4 cases of pain, and 2 cases of hair loss. The patients in the control group were complicated with bone marrow suppression in 14 cases, gastrointestinal reaction in 17 cases, fever in 5 cases, pain in 4 cases, and hair loss in 6 cases. The difference was statistically significant ( P < 0.05 ). It showed that zoledronic acid combined with chemotherapy could effectively improve the treatment efficiency and clinical benefit rate of patients with lung cancer spinal metastases, prolong the progression of the disease, reduce the degree of bone tissue damage, and would not increase chemotherapy adverse events.

This study assesses the prognosis of bone tumor chemotherapy. The expressions of P53 and NM23 were measured to analyze their relationship. The curative effect distributions of patients with positive and negative expression of P53 were not the same (x2 =10.513, P =0.016). P53 positive level was associated with nausea and vomiting (x2 = 18.664, P <0.05), oral mucositis (x2 = 23.346, P <0.05) and diarrhea (x2 = 16.514, P < 0.05), as well as incidence of complications. The 3-year survival rate was 38.3% for patients with P53 positive level and 31.4% for patients with negative, with a significant difference (Log rank x2 = 6.417, P = 0.011, HR = 1.784, 95%CI: 1.084–2.936). Adjuvant chemotherapy is an important treatment for osteosarcoma, but it has not achieved satisfactory outcomes in terms of improving the prognosis, and there are still problems of high recurrence and metastasis rates after surgery. After osteosarcoma treatment, it is faced tumor recurrence and metastasis and bone repair. The precise exploration of prognostic targets participates in this disease. This study thus explored the prognosis of two important tumor suppressor genes, and herein results showed that, the expression of human tumor suppressor gene P53 has an important effect on bone tumor patients receiving Folinic acid, fluorouracil and oxaliplatin (FOLFOX). The curative effect and safety of chemotherapy have a certain predictive effect, and play an important guiding role in tumor metastasis and recurrence after treatment, among which P53 can also predict the mid-term survival of patients.